Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week.
Race Oncology Chief Executive Peter Molloy will present on Monday 8 January, the opening day of the conference.
“The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium on the US investment calendar,” said Mr Molloy.
“The Biotech Showcase is a pivotal opportunity to present Race Oncology’s key drug Bisantrene and the Race investment story to more than eight thousand attendees from all over the world,” said Mr Molloy.
This is the first time Race has presented at the J.P. Morgan Biotech Showcase. The conference is part of the company’s strategy to expand its international profile.
“Presenting at international conferences help to build Race’s global profile among healthcare and biotech investors,” said Mr Molloy.
Over the last several months, Race has been meeting with potential investors in New York and London, who have experience investing in ASX-listed companies.
“The Race story has been positively received in New York, with some investors describing our business model as ‘unique’ and ‘exciting’,” said Mr Molloy.
During November, the company presented at the ‘Biotech & Money’ conference in London, and also attended the Jefferies Healthcare Conference.